EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:EPRSQ
Previous SymbolNASDAQ:EPRS
CUSIPN/A
Phone617-600-3497
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$580,000.00
Price / Sales0.04
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares26,180,000
Market Cap$20,000.00
OptionableNot Optionable
Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Frequently Asked Questions
What is Epirus Biopharmaceuticals' stock symbol?
Epirus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "EPRSQ."
How were Epirus Biopharmaceuticals' earnings last quarter?
Epirus Biopharmaceuticals Inc (OTCMKTS:EPRSQ) posted its quarterly earnings results on Tuesday, March, 15th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.07. The biopharmaceutical company had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.41 million. View Epirus Biopharmaceuticals' Earnings History.
Has Epirus Biopharmaceuticals been receiving favorable news coverage?
Press coverage about EPRSQ stock has trended negative this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Epirus Biopharmaceuticals earned a daily sentiment score of -2.6 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the company's share price in the near future.
Who are some of Epirus Biopharmaceuticals' key competitors?
Some companies that are related to Epirus Biopharmaceuticals include American Oriental Bioengineering (AOBI), Orexigen Therapeutics (OREXQ), Poniard Pharmaceuticals (PARD), Inspyr Therapeutics (NSPX), Pivotal Therapeutics (PVTTF), Advanced Accelerator Application (AAAP), Aerpio Pharmaceuticals (ARPO), Anthera Pharmaceuticals (ANTH), Aralez Pharmaceuticals (ARLZ), Argos Therapeutics (ARGS), ARMO Biosciences (ARMO), Biostar Pharmaceuticals (BSPM), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME) and Concordia International (CXRXD).
Who are Epirus Biopharmaceuticals' key executives?
Epirus Biopharmaceuticals' management team includes the folowing people:
- Mr. Jeff Kagy, VP of HR & Admin.
- Jason Yap, Head of Global Regulatory Affairs and Sr. Director
- Dr. Louis Boon, Head of CLG, Bioassay & Process Devel.
- Emile Van Corven Ph.D., Head of Analytical Devel. and Downstream PD
- Dr. Mark Melville Ph.D., Sr. Director of Process Devel.
How do I buy shares of Epirus Biopharmaceuticals?
Shares of EPRSQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Epirus Biopharmaceuticals' stock price today?
One share of EPRSQ stock can currently be purchased for approximately $0.0009.
How big of a company is Epirus Biopharmaceuticals?
Epirus Biopharmaceuticals has a market capitalization of $20,000.00 and generates $580,000.00 in revenue each year.
What is Epirus Biopharmaceuticals' official website?
How can I contact Epirus Biopharmaceuticals?
Epirus Biopharmaceuticals' mailing address is 699 BOYLSTON ST 8TH FLOOR, BOSTON MA, 02116. The biopharmaceutical company can be reached via phone at 617-600-3497 or via email at [email protected]
MarketBeat Community Rating for Epirus Biopharmaceuticals (OTCMKTS EPRSQ)
MarketBeat's community ratings are surveys of what our community members think about Epirus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EPRSQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPRSQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
